medigraphic.com
Boletín Médico del Hospital Infantil de México

2006, Number 3

<< Back

Bol Med Hosp Infant Mex 2006; 63 (3)

The hyperprostaglandin E syndrome in children.

Velásquez-Forero F, Cabeza-Salinas M, Román-Ramos R

Language: Spanish
References: 126
Page: 208-220
PDF size: 112.74 Kb.


ABSTRACT

In 1997, Welch identified in a child the hyperprostaglandin E syndrome, which is characterized by raised calcitriol, hypercalciuria and urinary hyperexcretion of PGE2. Welch hypothesized that hyperprostaglandin E increases the synthesis of calcitriol, increasing Ca absorption which causes hypercalciuria.
In this work analyze the existence of the clinical syndrome reported by Welch.
We review the experimental and clinical bibliography on the relationship between prostaglandins (PG) E and the calcitriol synthesis.
Observations in vivo, in vitro and in many clinical studies, showed that PG E, increased the calcitriol synthesis.
The review of medical literature proved that the PG E increases the synthesis of calcitriol and reproduces the hyperprostaglandin E syndrome. This has been rarely mentioned.
The hyperprostaglandin E syndrome exists in children. This syndrome could be present as a unic entity or superimposed to other pathologics.


REFERENCES

  1. Welch T. The hyperprostaglandin E syndrome: a hypercalciuric variant of Bartter’s syndrome. J Bon Miner Res.1997; 12: 1753.

  2. Restrepo R, Welch T, Hug G, Clark K, Bergstrom W. Hypercalciuria with Bartter’s syndrome: evidence for an abnormality of vitamin D metabolism. J Pediatr. 1989; 115: 397-404.

  3. Velásquez-Forero F, Valencia P, de León G, Llach F. Prostaglandin E1 increases the biosynthesis of calcitriol in rabbits. J Am Soc Nephrol (abstracts). 2004; 15: 737A; SU-PO949.

  4. Velásquez-Forero F, Valencia P, de León G, Llach F. Prostaglandin E1 increases in vitro synthesis of calcitriol in renal tubular cell cultures in the rabbits. J Am Soc Nephrol (abstracts). 2004; 15: 737A; SU-PO948.

  5. Treschel U, Taylor C, Bonjour J, Fleisch H. Influence of prostaglandins and of cyclic nucleotides on the metabolism of 25-hydroxyvitamin D3 in primary chick kidney cell culture. Biochem Biophys Res Commun. 1980; 9: 1210-6.

  6. Wark J, Larkins R, Eisman J, Wilson K. Regulation of 25-hydroxy-vitamin D-1a-hydroxylase in chick isolated renal tubules: effects of prostaglandin E2 furosemide and acetylsalicylic acid. Clin Sci (Lond). 1981; 61: 53-9.

  7. Kraemer S, Meade E, de Witt D. Prostaglandin endoperoxide synthase gene structure: identification of the transcriptional start site and 5’-flanking regulatory sequences. Arch Biochem Biophys. 1992; 293: 391-400.

  8. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties and functions. Physiol Rev. 1999; 79: 1193-226.

  9. Coleman R, Kennedy I, Humphrey P, Bunce K, Lumpley P. Prostanoids and their receptors. En: Emmett JC, editor. Comprehensive medicinal chemistry. Membranes and receptors. Oxford, UK: Pergamon Press; 1990 Vol. 3. p. 643-714.

  10. Coleman R, Grix S, Head S, Louttit J, Mallett A, Sheldrick. A novel inhibitory receptor in piglet saphenous vein. Prostaglandins. 1994; 47: 151-68.

  11. Hirata M, Hayashi Y, Ushikubi F, Yokota Y, Kageyama R, Nakanishi S, et al. Cloning and expression of cDNA for a human thromboxane A2 receptor. Nature. 1991; 349: 617-20.

  12. Funk C, Furci L, Fitzgerald GA, Grygorczyk R, Rochette C, Bayne MA, et al. Cloning and expression of a cDNA for the human prostaglandin E receptor EP1 subtype. J Biol Chem. 1993; 268: 26767-72.

  13. Katsuyama M, Nishigaki N, Sugimoto Y, Morimoto K, Negishi M, Narumiya S, et al. The mouse prostaglandin E receptor EP2 subtype: cloning, expression, and Northern blot analysis. FEBS Lett. 1995; 372: 151-6.

  14. Regan J, Bailey T, Donello J, Pierce K, Pepprl D, Zhang D, et al. Molecular cloning and expression of human EP3 receptors: evidence of three variants with differing carboxyl termini. Br J Pharmacol. 1994; 112: 377-85.

  15. Foord S, Marks B, Stolz M, Bufflier E, Fraser N, Lee M. The structure of the prostaglandin EP4 receptor gene and related pseudogenes. Genomics. 1996; 35: 182-8.

  16. Wong M, Sriussadaporn S, Tembe V, Favus M. Insulin-like growth factor I increases renal 1,25(OH)2D3 biosynthesis during low-P diet in adult rats. Am Physiol Soc. 1997; F698-F703.

  17. Favus M. Intestinal absorption of calcium, magnesium and phosphorus. En: Coe FL, Favus MJ, editores. Disorders of bone and mineral metabolism. New York: Raven Press; 1992. p. 57-81.

  18. Wilz D, Gray R, Dominguez J, Lemann J. Plasma 1,25-(OH)2-vitamin D concentrations and net intestinal calcium, phosphorus and magnesium absorption in humans. Ann J Clin Nutr. 1979; 32: 2052-60.

  19. Hughes M, Brumbaugh P, Haussler M, Wergedal J, Baylink D. Regulation of serum 1,25-dihydroxyvitamin D3 by calcium and phosphate in the rat. Science. 1975; 190: 578-9.

  20. Bito L. Accumulation and apparent active transport of prostaglandins by some rabbit tissues in vitro. J Physiol. 1972; 221: 371-87.

  21. Andersen N, Eggerman T, Harker L, Wilson C, De B. On the multiplicity of platelet prostaglandin receptors. I. Evaluation of competitive antagonism by aggregometry. Prostaglandins. 1980; 19: 711-35.

  22. Gardnier P, Collier H. Specific receptors for prostaglandins in airways. Prostaglandins. 1980; 19: 819-41.

  23. Pickles V. The myometrial actions of six prostaglandins: consideration of a receptor hypothesis. En: Bergstrom S, Samuelson B, editores. Nobel symposium. Prostaglandins. Stock-Holm: Almquist & Wicksell; 1967. Vol. 2. p. 79-83.

  24. Kennedy I, Coleman R, Humphrey P, Levy G, Lumley P. Studies on the characterization of prostanoid receptors: a proposed classification. Prostaglandins. 1982; 24: 667-89.

  25. Ushikubi F, Nakajima M, Hirata M, Okuma M, Fujiwara M, Naruyima S. Purification of the thromboxane A2/prostaglandin H2 receptor from human blood platelets. J Biol Chem. 1989; 264: 16496-501.

  26. Nusing R, Hirata M, Kakizuka A, Eki T, Ozawa K, Narumiya S. Characterization and chromosomal mapping of the human thromboxane A2 receptor gene. J Biol Chem. 1993; 268: 25253-9.

  27. Duncan A, Andersen L, Funk C, Abramovitz M, Adam M. Chromosomal localization of the human prostanoids receptor gene family. Genomics. 1995; 25: 740-2.

  28. Toh H, Ichikawa A, Narumiya S. Molecular evolution of receptors for eicosanoids. FEBS Lett. 1995; 361: 17-21.

  29. Honda Z, Nakamura M, Miki I, Minami M, Watanabe T, Seyama Y, et al. Cloning by functional expression of platelet-activating factor receptor from guinea-pig lung. Nature. 1991; 349: 342-6.

  30. Nakamura M, Honda Z, Izumi T, Sakanaka C, Mutoh H, Minami M, et al. Molecular cloning and expression of platelet-activating factor receptor from human leukocytes. J Biol Chem. 1991; 266: 20400-5.

  31. Fiore S, Maddox J, Perez H, Serhan C. Identification of a human cDNA encoding a functional high affinity lipoxin A4 receptor. J Exp Med. 1994; 180: 253-60.

  32. Yokomizo T, Izumi T, Chang K, Takuwa T, Shimizu T. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature. 1997; 387: 620-4.

  33. Regan J, Bailey T, Pepperl K, Pierce A, Bogadurdus J, Bonello C, et al. Cloning of a novel human prostaglandin receptor with characteristics of pharmacologically defined EP2 subtype. Mol Pharmacol. 1994; 46: 213-20.

  34. Raisz L, Martin T. Prostaglandins in bone and mineral metabolism. En: Bone Miner Res, Annual 2. Amsterdam: Excerpta Medica; 1983. p. 286-310.

  35. Bergmann P, Shoutens A. Prostaglandins and bone. Bone. 1995; 16: 485-8.

  36. Sato K, Kasono K, Fuji Y. Tumor necrosis factor type-a (cachectin) stimulates mouse osteoblast-like cells (MC3T3-E1) to produce macrophage-colony stimulating activity and prostaglandin E2. Biochem Biophys Res Commun. 1987; 145: 323-9.

  37. Kimble R, Matayoshi A, Vannice J, Kung V, Williams C, Pacifici R. Simultaneous block of interleukin-1 and tumor necrosis factor is required to completely prevent bone loss in the early postovariectomy period. Endocrinology. 1995; 126: 3054-61.

  38. Harrison J, Lorenzo J, Kawuaguchi H, Raisz L, Pilbeam C. Stimulation of prostaglandin E2 production by interleukin-1a and transforming growth factor a in osteoclastic MC3T3-El cells. J Bone Miner Res. 1994; 9: 817-23.

  39. Klein-Nulend J, Fall P, Raisz L. Comparison of the effects of synthetic human parathyroid hormone (PTH-(1-34))-related peptide of malignancy and bovine PTH-(1-34) on bone formation and resorption in organ culture. Endocrinology. 1990; 126: 7991-4.

  40. Klein-Nulend J, Pilbeam C, Harrison J, Fall P, Raisz L. Mechanism of regulation of prostaglandin production by parathyroid hormone, interleukin-1, and cortisol in cultured mouse parietal bones. Endocrinology. 1991; 128: 2503-10.

  41. Lanyon L. Control of bone architecture by functional load bearing. J Bone Miner Res.1992; 7: S369-S75.

  42. Chow J, Chambers T. Indomethacin has distinct early and late actions on bone formation induced by mechanical stimulation. Am J Physiol. 1994; 267: E287-E92.

  43. Feyen J, Raisz L. Prostaglandin production from sham operated oophorectomized rats: Effect of 17b-estradiol in vivo. Endocrinology. 1987; 121: 819-21.

  44. Miyaura C, Kusano K, Masuzawa T, Chaki O, Onoe Y, Aoyagi M, et al. Endogenous bone-resorption factors in estrogen deficiency: Cooperative effects of IL-1 and IL-6. J Bone Miner Res. 1995; 10: 1365-73.

  45. Kawaguchi H, Pilbeam C, Vargas S, Morse E, Lorenzo J, Raisz L. Ovariectomy enhances and estrogen replacement inhibits the activity of marrow factors which stimulate prostaglandin production in cultured mouse calvarie. J Bone Miner Res. 1995; 9: B133.

  46. Akatsu T, Takahashi N, Debari K, Morita I, Murota S, Nagata N, et al. Prostaglandins promote osteoclast-like cell formation by mechanism involving cyclic adenosine 3’, 5‘ monophosphate in mouse bone marrow cell cultures. J Bone Miner Res. 1989; 4: 29-35.

  47. Collins D, Chambers T. Effect of prostaglandins E1, E2 and F2a on osteoclast formation in mouse bone marrow cultures. J Bone Miner Res. 1991; 6: 157-64.

  48. Rawlinson S, Mohan S, Baylink D, Lanyon L. Exogenous prostacyclin, but not prostaglandin E2 produces similar responses in both G6PD activity and RNA production as mechanical loading, and increases, IGF-2 release, in adult cancellous bone in culture. Calcif Tissue Int. 1993; 53: 324-9.

  49. Zaman G, Suswillo R, Cheng M, Lanyon L. Effect of strain and strain-related prostanoids on mRNA expression of c-fos, IGF-I & IGF-II and TGFb. J Bone Miner Res. 1995; 9: 295.

  50. Ono K, Akatsu T, Murakami T, Nishikawa M, Yamamoto M, Kugai N, et al. Important role of EP4, a subtype of prostaglandin (PG) E receptor, in osteoclast formation from mouse marrow cells induce by PGE2. J Endocrinol. 1998; 158: R1-5 corrigendum 159: 527.

  51. Li X, Okada Y, Pilbeam C, Lorenzo J, Kennedy C, Breyer R, et al. Knockout of the murine prostaglandin EP2 receptor impairs osteoclastogenesis in vitro. Endocrinology. 2000; 141: 2054-61.

  52. Sakuma Y, Tanaka K, Suda M, Yasoda A, Natsui K, Tanaka I, et al. Crucial involvements of the EP4 subtype of prostaglandin E receptor in osteoclast formation by proinflammatory cytokines and lipopolysaccharide. J Bone Miner Res. 2000; 15: 218-27.

  53. Suzawa T, Miyaura C, Inada M, Maruyama T, Sugimoto Y, Ushikubi F, et al. The role of prostaglandin E receptor subtypes (EP1, EP2, EP3 and EP4) in bone resorption: analysis using specific agonists for respective EPs. Endocrinology. 2000; 141: 1554-9.

  54. Tomita M, Li X, Okada Y, Woodiel F, Young R, Pilbeam C, et al. Effects of selective prostaglandin EP4 receptor antagonist on osteoclast formation and bone resorption in vitro. Bone. 2002; 30: 159-63.

  55. Woo K, Emery J, Peabody J. Cortical hyperostosis: A complication of prolonged prostaglandin infusion in infants awaiting cardiac transplantation. Pediatrics. 1994; 93.

  56. Li X, Jee W, Li Y, Buckendahl P. Transient effects of subcutaneously administered prostaglandin E2 on cancellous and cortical bone in young adult dogs. Bone. 1990; 11: 353-64.

  57. Katz I, Jee W, Joffe I, Stein B, Takizawa M, Jacobs T, et al. Prostaglandin E2 Alleviates cyclosporin A-induced bone loss in the rat. J Bone Miner Res. 1992; 7: 1191-200.

  58. Jee W, Ueno K, Deng Y, Wooldbury D. The effects of prostaglandin E2 in growing rats: Increased metaphyseal hard tissue and corticoendosteal bone formation. Calcif Tissue Int. 1985; 37: 148-56.

  59. Nordin R, Jee W, High W. The role of prostaglandins in bone in vivo. Prostaglandins Leukot Essent Fatty Acids. 1990; 41: 139-49.

  60. Takada M, Yamamoto I, Kigami Y, Ohnaka Y, Morita R. Chronic intramedullary infusion of prostaglandin E2 stimulates bone formation both in the bone marrow and in the periosteum. Endocr J. 1995; 42: 323-30.

  61. Engesaeter L, Sudmann B, Sudmann E. Fracture healing in rats inhibited by locally administered indomethacin. Acta Orthop Scand. 1992; 63: 330-3.

  62. Scutt A, Bertram P. Bone marrow cells are targets for the anabolic actions of prostaglandin E2 on bone: induction of a transition from nonadherent to adherent osteoblast precursors. J Bone Miner Res. 1995; 10: 474-87.

  63. Askew F, Bourdillon R, Bruce H, Jenkins R, Webster T. The distillation of vitamin D. Proc R Soc Lond B Biol Sci. 1931; 107: 76-90.

  64. Windaus A, Schenck F, von Wender F. Uber das antirachitisch wirksame Bestrahlungsprodukt aus 7-dehydro-cholesterin. Z Physiol. 1936; 241: 100-3.

  65. Blunt J, de Luca H, Schones H. 25-Hydroxycholecalciferol. A biologically active metabolite of vitamin D3. Biochemistry. 1968; 7: 3317-22.

  66. Fraser D, Kodicek E. Unique biosynthesis by kidney of a biological active vitamin D metabolite. Nature. 1970; 228: 764-6.

  67. Holic M, Schnoes H, de Luca H, Sudda T, Cousins R. Isolation and identification of 1,25-dihydroxy-cholecalciferol. A metabolite of vitamin D active intestine. Biochemistry. 1971; 10: 2799-804.

  68. Lawson D, Fraser D, Kodicek E, Morris H, Williams D. Identification of 1,25-dihydroxycholecalciferol, a new kidney hormone controlling calcium metabolism. Nature. 1971; 230: 228-30.

  69. Demay M, Kierman M, de Luca H. Sequences in the human parathyroid hormone gene that bind the 1,25-dihydroxyvitamin D3 receptor and mediates transcriptional repression in response to 1,25-dihydroxyvitamin D3. Proc Natl Acad Sci USA. 1992; 89: 8097-101.

  70. Navah-Many T, Marx R, Koshet E, Pike J, Silver J. Regulation of 1,25-dihydroxyvitamin D3 receptor gene expression by 1,25-dihydroxyvitamin D3 in the parathyroid in vivo. J Clin Invest. 1990; 86: 1968-75.

  71. Merke J, Hugel U, Zlotkowski A, Szabo A, Bommer J, Mall G, et al. Diminished parathyroid 1,25-(OH)2D3 receptors in experimental uremia. Kidney Int. 1987; 32: 350-3.

  72. Brown A, Dusso A, Lopez-Hilkeer S, Lewis-Finch J, Grooms P, Slatopolsky E. 1,25(OH)2D receptors are decreased in parathyroid glands from chronically uremic dogs. Kidney Int. 1989; 35: 19-23.

  73. Denda M, Finch J, Brown AJ, Nishi Y, Kubodera N, Slatopolsky E. 1,25-Dihydroxyvitamin D3 and 22-oxacalcitriol prevent the decrease in vitamin D receptor content in the parathyroid glands of uremic rats. Kidney Int. 1996; 50: 34-9.

  74. Fu G, Lin D, Zhang M, Bikle D, Shackleton C, Miller W, et al. Cloning of human 25-hydroxyvitamin D-1a-hydroxylase and mutations causing vitamin D-dependent rickets type I. Mol Endocrinol. 1997; 11: 1961-70.

  75. Portale A, Miller W. Human 25-hydroxyvitamin D-1a-hydroxylase: cloning, mutations and gene expression. Pediatr Nephrol. 2000; 14: 620-5.

  76. Reichel H, Koeffler H, Norman A. Production of 1a,25-dihydroxyvitamin D3 by hematopoietic cells. Prog Clin Biol Res. 1990; 332: 81-97.

  77. Halhali A, Díaz L, Sánchez I, Garabedian M, Bourges H, Larrea F. Effects of IGF-I on 1,25-dihydroxyvitamin D3 synthesis by human placenta in culture. Mol Hum Reprod. 1999; 5: 771-6.

  78. Su P, Rennert H, Shayiq R. A cDNA encoding a rat mitochondrial cytochrome P450 catalyzing both the 26-hydroxylation of cholesterol and 25-hydroxylation of vitamin D3: gonadotropic regulation of the cognate mRNA in ovaries, DNA. Cell Biol. 1990; 9: 657-65.

  79. Ohyama Y, Noshiro M, Okuda K. Cloning and expression of cDNA encoding 25-hydroxyvitamin D3 24-hydroxylase. FEBS Lett. 1991; 278: 195-8.

  80. Chen K, Prahl J, de Luca H. Isolation and expression of human 1,25-dihydroxyvitamin D3 24-hydroxylase cDNA. Proc Natl Acad Sci USA. 1992; 90: 4543-7.

  81. Chen K, de Luca H. Cloning of the human 1 alpha, 25-dihydroxyvitamin D3-24-hydroxylase gene promoter and identification of two vitamin D-responsive elements. Biochim Biophys Acta. 1995; 1263: 1-9.

  82. Fu G, Portale A, Miller W. Complete structure of the human gene the vitamin D-1a-hydroxylase, P450c1a. DNA. Cell Biol. 1997; 12: 1499-507.

  83. Monkawa T, Yoshida Y, Wakino S. Molecular cloning of cDNA and genomic DNA for human 25-hydroxyvitamin D3 1a-hydroxylase. Biochem Biophys Res Commun. 1997; 239: 527-33.

  84. Shinki T, Shimada H, Wakino S. Cloning and expression of rat 25-hydroxyvitamin D3-1ahydroxylase Cdna. Proc Natl Acad USA. 1997; 94: 12920-5.

  85. St-Arnaud R, Messerlian S, Moir J, Omdahl J, Glorieux F. The 25-hydroxyvitamin D 1-alpha-hydroxylase gene maps to the pseudovitamin D-deficiency rickets (PDDR) disease locus. J Bone Miner Res. 1997; 12: 1552-9.

  86. Takeyama K, Kitanaka S, Sato T, Kobori M, Yanagisawa J, Kato S. 25-Hydroxyvitamin D3 1a-hydroxylase and vitamin D synthesis. Science. 1997; 277: 1827-30.

  87. Langman C, Favus M, Bushinsky D, Coe F. Effects of dietary calcium restriction on 1,25-dihydroxyvitamin D3 net synthesis by rat proximal tubules. J Lab Clin Med. 1985; 106: 286-92.

  88. Wong M, Sriussadaporn S, Tembe V, Favus M. Insulin-like growth factor I increases renal 1,25(OH)2D3 biosynthesis during low-P diet in adult rats. Am Physiol Soc. 1997; F698-F703.

  89. Christakos S, Friedlander E, Frandsen B, Norman A. Studies on the mode of action of calciferol. XIII. Development of a radioimmunoassay for vitamin D-dependent chick intestinal calcium-binding protein and tissue distribution. Endocrinology. 1979; 104: 1495-503.

  90. Pike J. Vitamin D3 receptors. Structure and function in transcription. Ann Rev Nutr. 1991; 11: 189-216.

  91. Minghetti P, Norman A. 1,25(OH)2-Vitamin D3 receptors: Gene regulation and genetic circuitry. FASEB J. 1988; 2: 3043-53.

  92. Glass C, Rose D, Rosenfeld M. Nuclear receptor coactivators. Curr Opin Cell Biol. 1997; 9: 222-32.

  93. Norman A, Song X, Zanello L, Bula C, Okamura W. Rapad and genomic biological responses are mediated by different shapes of the agonist steroid hormone, 1alpha,25(OH)2 vitamin D3. Steroids. 1991; 64: 120-8.

  94. Baran D, Quail J, Ray R, Leszyk J, Honeyman T. Identification of the membrane protein that binds 1a,25dihidroxyvitamin D3 and is involved in the rapid actions of the hormone. Bone. 1998; 23 Supl: S176.

  95. Li Y, Meuse J, Guo J, Bringhurst F, Demay M. Analysis of rapid cellular response to vitamin D treatment in mouse osteoblasts lacking the vitamin D receptor. Bone. 1998; 23 Supl: S263.

  96. Nemere I, Dormanen M, Hammon M, Okamura W, Norman A. Identification of specific binding protein for 1a,25-dihydroxyvitamin D3 in basal-lateral membranes of chick intestinal epithelium and relationship to transcaltachia. J Biol Chem. 1994; 269: 23750-6.

  97. Brown A, Dusso A, Slatopolsky E. Vitamin D. Am Physiol Soc. 1999; F157-F75.

  98. Schwarz U, Amann K, Orth S, Simonavicience A, Wessels S, Ritz E. Effect of 1,25(OH)2 vitamin D3 on glomeruloesclerosis in subtotally nephrectomized rats. Kidney Int. 1998; 53: 1696-705.

  99. Hariharan S, Hong S, Hsu A, Gartside P, Ooi B. Effect of 1,25-dihydroxyvitamin D3 on mesangial cell proliferation. J Lab Clin Med. 1991; 117: 423-9.

  100. Konety B, Lavelle J, Pirtskalaishivili G, Dhir R, Meyers S, Nguyen T, et al. Effects of vitamin D (calcitriol) on transitional cell carcinoma of the bladder in vitro and in vivo. J Urol. 2001; 165: 253-8.

  101. Celli A, Treves C, Stio M. Vitamin D receptor in SH-SY5Y human neuroblastoma cells and effect of 1,25-dihydroxyvitamin D3 on cellular proliferation. Neurochem Int. 1999; 34: 117-24.

  102. Tanaka Y, Wu A, Ikekaya N, Iseki K, Kawai M, Kobayashi Y. Inhibition of HT-29 human colon cancer growth under the capsule of severe combined immune-deficient mice by an analogue of 1,25-dihydroxyvitamin D3, DD-003. Cancer Res. 1994; 54: 5148-53.

  103. Lillevang S, Rosenkvist J, Andersen C, Larsen S, Kemp E, Kristen T. Single and combined effects of the vitamin D analogue KH1060 and cyclosporin A on mercuric-chloride-induced autoinmune disease in the BN rat. Clin Exp Immunol. 1992; 88: 301-6.

  104. Lemire J. The role of vitamin D in immunosuppresion. Lesson from autoimmunity and transplantation. En: Feldman D, Pike JW, Glorieux FH, editores. Vitamin D. San Diego, CA: Academic; 1997. p. 1167-81.

  105. Jordan S, Shibuka R, Mullen Y. 1,25-Dihydroxyvitamin D3 prolongs skin survival in mice. En: Norman AW, Schaefer K, Grigoleit HG, von Herrath D, editores. Vitamin D: molecular, cellular and clinical endocrinology. Berlin, Germany: de Gruyter; 1988. p. 346-7.

  106. Veyron P, Pamphile R, Binderup L, Touraine J. Two novel vitamin D analogues. KH 1060 CB 966, prolongs skin allograft survival in mice. Transplant Immunol. 1993; 1: 72-6.

  107. Veyron P, Pamphile R, Binderup L, Touraine J. New 20-epi-vitamin D3 analogues: Immunosuppressive effects on skin allograft survival. Transplant Proc. 1995; 27: 450.

  108. Lemire J, Archer D, Khulkarni A, Uskokovic M, Stepkowki S. Prolongation of the survival of murine cardiac allografts by the vitamin D3 analogue 1,25-dihydroxy-delta-16-cholecalciferol. Transplantation. 1992; 54: 762-3.

  109. Jordan S, Nigata M, Mullen Y. 1,25-Dihydroxyvitamin D3 prolongs rat cardiac allograft survival. En: Norman A, Schaefer K, Grigolcit H, von Herrath D, editores. Vitamin D: molecular, cellular and clinical endocrinology. Berlin, Germany: de Gruyter; 1988. p. 334-5.

  110. Johnsson C, Tufveson G. A vitamin D analogue with immunosuppressive effects on heart and small bowel grafts. Transplant Int. 1994; 7: 392-7.

  111. Lewin E, Olgnard K. The in vivo effect of a new, in vitro, extremely potent vitamin D3 analogue KH1060 on the suppression of renal allograft rejection in the rat. Calcif Tissue Int. 1994; 54: 150-4.

  112. Johnsson C, Binderup L, Tufveson G. The effects of combined treatment with the novel vitamin D analogue MC 1288 and cyclosporine A on cardiac allograft survival. Transplant Immunol.1995; 3: 245-50.

  113. Llach F, Velásquez-Forero F. Secondary hyperparathyroidism in chronic renal failure: patohogenic and clinical aspects. Am J Kidney Dis. 2001; 38: S20-S33.

  114. Binderup L, Kragballe K. Origin of the use of calcipotriol in psoriasis treatment. Rev Contemp Pharmacother. 1992; 3: 401-9.

  115. Slatopolsky E, Finch J, Ritter C, Brown A. A new analog of calcitriol, 19-nor-1,25(OH)2D2, suppresses parathyroid gland hormone secretion in uremic rats in the absence of hipercalcemia. Am J Kidney Dis. 1995; 26: 852-60.

  116. Slatopolsky E, Finch J, Ritter C, Takahashi F. Effects of 19-nor-1,25(OH)2D2, a new analogue of calcitriol, on secondary hyperparathyroidism in uremic rats. Am J Kidney Dis. 1998; 32: S40-S7.

  117. Frazao S, Bower J, Kelley B, Rodriguez H, Norris K, Robertson J, et al. Intermittent doxercalciferol (1 alpha-hydroxyvitamin D3) therapy for secondary hyperparathyroidism. Am J Kidney Dis. 2000; 36: 550-661.

  118. Maung H, Elangovan L, Frazao J, Bower J, Kelley B, Acchiardo S, et al. Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D2) in dialysis patients with secondary hyperparathyroidism. A sequential comparison. Am J Kidney Dis. 2001; 37: 532-43.

  119. Weber K, Goldber M, Stangsainger M, Erben R.1ahydroxyvitamin D2 is less toxic but not bone selective relative to 1a hydroxivitamin D3 in ovarectomized rats. J Bone Miner Res. 2001; 16: 639-44.

  120. Seyberth H, Rascher W, Scheweer H, Kuhl P, Mehls O, Sharer K. On genital hypokalemia with hypercalciuria in preterm infants: a hyperprostaglandinuric tubular syndrome different from Bartter’s syndrome. J Pediatr. 1985; 107: 694-701.

  121. McCredie D, Rotenberg E, Williams A. Hypercalciuria in potassium-losing nephropathy: a variant of Bartter’s syndrome. Aust Pediatr J. 1974; 10: 286-95.

  122. Dillon MJ, Shah V, Mitchell MD. Bartter’s syndrome, 10 cases in childhood-results of long-term indomethacin therapy. QJ Med. 1979; 48: 429-46.

  123. Seyberth J, Sergen D, Morgan J, Sweetman B, Potts J Jr, Oates J. Prostaglandins as mediators of hipercalcemia associated with certain types of cancer. N Engl J Med. 1975; 293: 1278-83.

  124. Houser M, Zimmerman B, Davidman M, Smith C, Sinaiko A, Fish A. Idiopathic hypercalciuria associated with hyperreninemia and high urinary prostaglandin E. Kidney Int. 1984; 26: 176-82.

  125. Hasanoglu A, Ercan Z, Buyan N, Memioglu N, Hasanoglu E. Parathormone, 1,25 dihydroxyvitamin D and prostaglandin E2 correlation in children with idiopatic hypercalciuria. Prostaglandins Leukot Essent Fatty Acids. 1997; 56: 235-7.

  126. Velásquez-Forero F. Síndrome de exceso de prostaglandina E en conejos. Nefrologia. 2005; 25: 83-9.




2020     |     www.medigraphic.com